IL-23 (Interleukin-23): Complete Research Profile — p19/p40 Heterodimer, IL-23R Signaling, Th17 Cell Maintenance, and the Immunology of Autoimmune Disease Research (2026)

# IL-23 (Interleukin-23): Complete Research Profile — p19/p40 Heterodimer, IL-23R Signaling, Th17 Cell Maintenance, and the Immunology of Autoimmune Disease Research (2026)

> RUO Disclaimer: IL-23 cytokine and all related research reagents described in this article are for Research Use Only. Not for use in human or animal subjects. Not intended for diagnostic or therapeutic applications.

Introduction to IL-23: The Th17-Sustaining Cytokine

Interleukin-23 (IL-23) is a heterodimeric cytokine that has emerged as one of the most therapeutically actionable immunological mediators of the past two decades. First identified in 2000 by Oppmann and colleagues, IL-23 was initially recognized for its structural homology to IL-12 — both cytokines share the IL-12B (p40) subunit — yet its biological profile is distinctly its own (PMID: 11114383). Where IL-12 drives interferon-γ (IFN-γ) production and Th1 cell differentiation, IL-23 selectively amplifies and sustains Th17 lymphocyte populations, thereby governing a fundamentally different branch of adaptive immunity.

The IL-23/IL-17 axis has proven central to the pathogenesis of numerous autoimmune and inflammatory conditions — most prominently psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and ankylosing spondylitis. As a result, IL-23 has become one of the most intensively studied cytokine targets in biomedical research, spawning a class of anti-p19 and anti-p40 biologic antagonists that have reshaped immunology research paradigms globally.

This article provides a comprehensive research profile of IL-23: its molecular biology, receptor system, downstream signaling, immunological functions, disease associations, and current landscape as a research reagent.

---

Molecular Structure of IL-23

IL-23 is a heterodimeric glycoprotein composed of two non-covalently associated subunits:

• •IL-23A (p19): A 19 kDa polypeptide encoded by the IL23A gene on chromosome 12q13.3. The p19 subunit is IL-23-specific and not shared with any other known cytokine. It adopts a four-helix bundle structure characteristic of the long-chain cytokine superfamily, with a topology that diverges from IL-12A (p35) in the loop regions critical for receptor engagement.
• •IL-12B (p40): A 40 kDa glycoprotein encoded by the IL12B gene on chromosome 5q33.3. The p40 subunit is shared with IL-12 (where it pairs with IL-12A/p35) and serves as the structural scaffold enabling receptor docking via its fibronectin type III-like domains.

A disulfide bond between p19 and p40 is essential for cytokine secretion and biological activity. The p40 subunit can also exist as a homodimer (p40)₂ that competes with intact IL-23 and IL-12 for receptor binding and has been studied as a naturally occurring decoy antagonist.

Gene Expression and Cellular Sources

IL-23 is predominantly secreted by innate immune cells at barrier surfaces:

• •Dendritic cells — especially DC2s (CD11c+CD14+ lamina propria DCs), plasmacytoid DCs, and Langerhans cells in the skin
• •Macrophages and monocyte-derived cells — particularly following TLR2, TLR4, and TLR9 engagement by microbial PAMPs
• •Non-classical monocytes in circulation during systemic inflammation
• •Certain epithelial cells at mucosal interfaces under pathological conditions

Expression of IL-23A (p19) is tightly regulated at the transcriptional level, controlled by NF-κB, AP-1, IRF5, and STAT3 in response to inflammatory stimuli. The IL-12B (p40) subunit is somewhat less tightly controlled and can be produced in excess of p19, explaining the accumulation of (p40)₂ homodimers in inflamed tissue.

---

The IL-23 Receptor Complex

IL-23 signals through a heterodimeric receptor complex composed of two chains:

IL-23R

Encoded by IL23R on chromosome 1p31.3, IL-23R is the IL-23-specific binding chain. Crucially, variants in IL23R — most notably the Arg381Gln (rs11209026) polymorphism — confer substantial protection from Crohn's disease, psoriasis, ulcerative colitis, and ankylosing spondylitis, providing the strongest genetic proof for the IL-23 pathway in human autoimmune disease pathogenesis.

IL-12Rβ1

Encoded by IL12RB1, this receptor subunit is shared with IL-12 (where it pairs with IL-12Rβ2). IL-12Rβ1 binds the p40 subunit, while IL-23R engages p19 — the same complementary architecture seen in the IL-12/IL-12Rβ1/IL-12Rβ2 complex.

IL-23R Expression Pattern

IL-23R is expressed on a restricted set of immune cell populations:

This restricted expression explains why IL-23 acts specifically as a Th17/ILC3 axis amplifier rather than a broad T cell activator.

---

JAK-STAT Signaling Downstream of IL-23

IL-23 receptor engagement initiates a canonical cytokine signaling cascade:

Step 1 — Receptor dimerization: IL-23 binding induces conformational change in the IL-23R/IL-12Rβ1 heterodimer.

Step 2 — JAK activation:

• •JAK2 is constitutively associated with IL-23R and becomes activated upon receptor engagement
• •TYK2 is associated with IL-12Rβ1 and is transphosphorylated by JAK2

Step 3 — STAT recruitment and phosphorylation: Activated JAK2 and TYK2 phosphorylate tyrosine residues on the intracellular tails of both receptor chains, creating SH2-domain docking sites for STAT proteins.

STAT Activation Profile

• •STAT3 (dominant): Phospho-STAT3 homodimerizes, translocates to the nucleus, and drives transcription of IL17A, IL17F, IL22, RORC, and MMP genes. This is the primary driver of Th17 effector programming.
• •STAT4 (secondary): Contributes to IFN-γ co-production in "ex-Th17" or Th1/17 hybrid cells; STAT4 activation distinguishes IL-23's long-term from IL-12's acute IFN-γ effects.
• •STAT1: Activated modestly; contributes to antimicrobial gene expression in macrophages.

Key Transcriptional Targets

IL-23/STAT3 signaling upregulates:

• •RORC (RORγt): Th17 master transcription factor
• •IL17A, IL17F: Effector cytokines driving granulopoiesis and epithelial antimicrobial responses
• •IL22: Epithelial barrier cytokine with dual homeostatic and pathological roles
• •CXCR4, CCR6: Chemokine receptors directing Th17 tissue homing
• •BCL6: Partial Tfh programming in certain lymphoid contexts

---

IL-23 and Th17 Cell Biology

The Critical Distinction: Differentiation vs. Maintenance

A fundamental conceptual advance in IL-23 biology is recognizing that IL-23 is not required for initial Th17 differentiation — that early process is driven by TGF-β + IL-6 (in murine systems) or IL-1β + IL-6 + IL-21 (in human systems), which induce RORγt. Instead, IL-23 is required for Th17 cell expansion, survival, and pathogenic transformation.

"Pathogenic Th17" cells — those that co-produce IL-17A and IFN-γ, express both RORγt and T-bet, and drive tissue-destructive inflammation — require chronic IL-23 exposure for their emergence. This was demonstrated definitively when IL-23-deficient mice showed failure of autoimmune disease despite intact Th17 differentiation (PMID: 12610626).

Th17 vs. Non-Pathogenic Th17

IL-23 promotes a "pathogenic" Th17 transcriptional program distinct from homeostatic Th17:

IL-23 and Innate-Like IL-17 Producers

Beyond conventional Th17 cells, IL-23 acts on innate-like populations that provide rapid IL-17A without antigen-specific TCR stimulation:

• •γδ T cells: Particularly Vγ4+ and Vγ6+ subsets in mouse; Vδ2+ in humans
• •ILC3s: Especially NCR- ILC3s in gut lamina propria and lymph nodes
• •MAIT cells: IL-23R-expressing mucosal-associated invariant T cells in inflammatory contexts

This "innate" IL-23-responsive compartment provides early IL-17A production before adaptive responses develop and is critical for host defense against extracellular pathogens including Candida albicans and Klebsiella pneumoniae.

---

IL-23 in Autoimmune Disease Biology

Psoriasis and Psoriatic Arthritis

Psoriasis is characterized by a chronic IL-23-driven inflammatory circuit in the dermis and epidermis:

1. Trigger phase: Keratinocyte stress activates dermal plasmacytoid DCs and monocyte-derived DCs, inducing IL-23 secretion

2. Amplification: Dermal IL-23 expands skin-resident γδ T cells and ILC3s, which produce IL-17A and IL-22

3. Effector phase: IL-17A signals through IL-17RA/RC on keratinocytes, inducing CXCL1, CXCL8, β-defensins, and S100 proteins — recruiting neutrophils and amplifying the inflammatory cascade

4. Chronicity: IL-23 sustains pathogenic Th17/γδ T cell populations in skin tissue-resident memory compartments

Genome-wide association studies (GWAS) have confirmed strong associations with IL23A, IL23R, IL12B, and downstream pathway genes including IL17A, IL17F, IL17RA, and STAT3, cementing the genetic architecture of the IL-23 axis in psoriasis.

In psoriatic arthritis (PsA), IL-23 acts at entheseal sites (tendon and ligament insertions into bone), where tissue-resident ILC3s and γδ T cells expressing IL-23R respond to locally secreted IL-23, producing IL-17 and IL-22 that drive osteoclastogenesis, enthesitis, and synovial inflammation.

Inflammatory Bowel Disease

In the gut, IL-23 occupies a critical position bridging microbial sensing to adaptive mucosal inflammation:

• •Crohn's disease: Dysbiosis and barrier dysfunction expose lamina propria DCs (particularly DC2s) to bacterial PAMPs, driving excess IL-23 secretion. This amplifies intestinal Th17 responses, ILC3 activity, and drives transmural inflammation characteristic of Crohn's. The IL23R Arg381Gln protective polymorphism provides ~3-fold protection from Crohn's disease — among the strongest single-SNP protective effects in IBD genetics.
• •Ulcerative colitis: IL-23 contributions are anatomically compartmentalized, with colonic DCs and macrophages driving IL-23-dependent ILC3/IL-22 dysregulation in the mucosa.

Blockade of the IL-23 pathway (via ustekinumab anti-p40 or risankizumab/guselkumab anti-p19) has demonstrated efficacy in both Crohn's and UC research trials, validating the pathway causally (PMID: 27959607).

Axial Spondyloarthritis and Ankylosing Spondylitis

IL-23 drives entheseal inflammation in axial spondyloarthritis (axSpA) through a distinct mechanism from its role in psoriasis or IBD. Key research findings:

• •Entheseal tissue contains a resident population of IL-23R+ γδ T cells and ILC3s that respond to local IL-23 independently of systemic adaptive immunity
• •IL-23-induced IL-17 and IL-22 in entheseal tissue promote osteoblast differentiation via Wnt signaling pathways
• •This contributes to the paradox of bone erosion alongside new bone formation (syndesmophytes) characteristic of advanced ankylosing spondylitis

---

IL-23 and Cancer Biology

Tumor-Promoting Functions

IL-23 has emerged as a pro-tumorigenic cytokine in several contexts:

• •Immune evasion: Tumor-associated macrophages (TAMs) and tumor-infiltrating DCs secrete IL-23, which suppresses NK cell activity and promotes Th17 accumulation over cytotoxic CD8+ T cell responses in the tumor microenvironment (TME)
• •STAT3 oncogenic signaling: IL-23-induced STAT3 activation in tumor-infiltrating immune cells and some tumor cells themselves upregulates anti-apoptotic proteins (BCL-XL, MCL-1), angiogenic factors, and immune checkpoint molecules
• •Skin carcinogenesis models: IL-23-deficient mice show reduced susceptibility to DMBA/TPA-induced skin tumor development, suggesting a tumor-promoting role for endogenous IL-23

Tumor-Suppressing Contexts

In certain murine tumor models, IL-23 promotes ILC3-mediated tumor surveillance through IL-22 effects on stress-ligand expression. The net oncological outcome depends on TME composition, tumor immunogenicity, and the relative abundance of Th17 vs. cytotoxic effectors in the infiltrate.

---

IL-23 in Gut Mucosal Immunity and Microbiome Interactions

Beyond inflammatory disease, IL-23 plays homeostatic roles in intestinal immune regulation:

• •Homeostatic ILC3 support: Low-level IL-23 from lamina propria DCs sustains ILC3 production of IL-22, maintaining colonocyte goblet cell function, mucin secretion, tight junction proteins (claudin-1, occludin), and RegIIIγ/α antimicrobial peptides
• •Segmented filamentous bacteria (SFB) sensing: In murine intestines, SFB colonization drives DC IL-23 production and Th17 generation in the lamina propria — one of the clearest mechanistic links between a commensal organism and the IL-23/Th17 axis
• •Microbiota-dependent IL-23 calibration: Germ-free mice have severely reduced intestinal Th17 cells and ILC3 IL-22 output, both partially restored by IL-23 administration — demonstrating the microbiome-IL-23 dependency

---

Anti-IL-23 Research Tools and Antagonist Biologics

Anti-p19 Antibodies (IL-23-Selective)

These reagents selectively block IL-23 without affecting IL-12, providing mechanistic specificity for research applications:

• •Guselkumab: Anti-p19 IgG1λ; DISCOVER-1 and DISCOVER-2 trials characterized joint and skin outcomes in PsA. In vitro RUO use: complete suppression of IL-23-induced STAT3 phosphorylation while preserving IL-12-induced STAT4 activation.
• •Tildrakizumab: Anti-p19 IgG1κ; studied in phase III RESURFACE trials for plaque psoriasis. Smaller MW than risankizumab/guselkumab; used in RUO assays requiring precise stoichiometric blocking.

Anti-p40 Antibodies (Dual IL-12/IL-23 Blockade)

• •Ustekinumab: Anti-p40 IgG1; the first approved biologic in this class, blocking both IL-12 and IL-23. Used in research when combined IL-12/IL-23 pathway suppression is desired as a comparator to p19-selective agents. UNIFI and CERTIFI trial data in Crohn's disease established proof-of-concept for intestinal IL-23 blockade (PMID: 27959607).

JAK/TYK2 Pathway Research Tools

Because IL-23 signals through JAK2/TYK2:

• •TYK2 inhibitors (deucravacitinib, brepocitinib): Selective TYK2 inhibition blocks both IL-23 and type I/III IFN receptor signaling; the pseudokinase mechanism of deucravacitinib provides allosteric selectivity that spares JAK1/2/3
• •Pan-JAK inhibitors (tofacitinib, baricitinib): Broad JAK suppression covers IL-23, IL-12, and multiple other cytokine pathways; used in research contexts where comparative pathway ablation is desired
• •STAT3 inhibitors: Direct STAT3 decoys and small-molecule inhibitors allow downstream IL-23 pathway blockade independent of receptor-level events

---

Research Models and In Vitro Systems

Murine Models for IL-23 Research

• •IL-23p19 overexpression transgenic mice: Develop spontaneous systemic inflammation including skin, gut, and joint pathology — providing mechanistic insight into IL-23-driven disease without exogenous stimuli
• •Recombinant IL-23 injection models: Intraplantar or intraauricular injection of rIL-23 delivers rapid tissue-level Th17 inflammation for pharmacological testing with short timelines
• •T cell transfer colitis with IL-23 modulation: CD4+CD45RBhi transfer into Rag1-/- recipients, combined with anti-IL-23 neutralization, enables dissection of IL-23 requirements in colitis pathogenesis
• •IL-23R reporter mice: IL-23R-GFP knockin models enable FACS-sorting and transcriptomic profiling of bona fide IL-23-responsive cell populations in vivo

Human Ex Vivo Systems

• •Psoriatic skin explants: Biopsy cultures stimulated with anti-p19 or anti-p40 antibodies, measuring reductions in IL-17A, IL-22, and CXCL8 — mapping the cellular hierarchy of IL-23 responses
• •PBMC stimulation: Recombinant IL-23 stimulation of peripheral blood mononuclear cells enables STAT3 phosphoflow cytometry, intracellular cytokine staining, and gene expression profiling
• •Intestinal organoid co-culture: Colonoid monolayers co-cultured with IL-23-stimulated immune cells model IL-22 signaling effects on epithelial tight junctions and antimicrobial peptide output

Recombinant IL-23 for Laboratory Research

Recombinant human IL-23 (rhIL-23) is produced as a research reagent in HEK293 or CHO expression systems, either as a covalent p19/p40 fusion protein or as a non-covalent heterodimer. Key quality parameters:

• •Bioactivity verification: STAT3 phosphorylation in primary human CD4+ T cells or IL-23R-expressing reporter lines; EC50 typically 0.5–5 ng/mL
• •Endotoxin specification: <1 EU/μg; critical to prevent confounding TLR4-mediated innate activation in immune cell assays
• •Storage: -80°C in carrier protein (0.1% BSA); minimize freeze-thaw cycles; aliquot upon first thaw

---

IL-23 Connections to Other Research Targets

IL-23 is embedded in a dense cytokine interaction network. Researchers may benefit from cross-referencing these platform profiles:

• •IL-12: The structural "parent" sharing the p40 subunit; drives Th1/IFN-γ axis — the biological counterpoint to IL-23's Th17 axis. Anti-p40 research tools (ustekinumab) block both simultaneously.
• •IL-17A: The primary downstream effector cytokine sustained by IL-23 in Th17 cells; the IL-23 → Th17 → IL-17A cascade is the core mechanistic axis in psoriasis and axSpA research.
• •IL-6: Acts upstream of IL-23 in Th17 differentiation (TGF-β + IL-6 → Th17 initiation); shares STAT3 as a core signaling output.
• •IL-1β: Critical for human Th17 differentiation (IL-1β + IL-6 + IL-21); cooperates with IL-23 in sustaining IL-17A production at mucosal surfaces.
• •TNF-α: Co-produced in psoriatic plaques and Crohn's lesions; combined IL-23 + TNF axis research models the full pathological inflammatory milieu in tissue explants.
• •IL-10: The dominant counter-regulatory cytokine opposing IL-23-driven inflammation; IL-10-deficient mice develop spontaneous colitis driven partially by unchecked IL-23/Th17 axis activity.
• •IFN-γ: Produced by pathogenic "ex-Th17" cells that co-express RORγt and T-bet under chronic IL-23 stimulation; serves as a marker of Th17→Th1 plasticity in research models.

---

Landmark Research Studies

IL-23 identification (2000): Oppmann et al. identified the p19 subunit and described IL-23 as a novel IL-12 family cytokine with overlapping but distinct biological activities, establishing the p19/p40 heterodimeric architecture (PMID: 11114383).

IL-23 drives autoimmune neuroinflammation (2003): Cua et al. demonstrated that IL-23 — not IL-12 — is the critical cytokine for experimental autoimmune encephalomyelitis, overturning the prevailing Th1 hypothesis and redirecting the entire autoimmunity research field toward the IL-23/Th17 axis (PMID: 12610626).

IL-23 expands pathogenic Th17 (2005): Langrish et al. showed that IL-23-driven CD4+ T cells produce IL-17 and are sufficient to transfer inflammatory disease, establishing Th17 cells as the key IL-23 effector population (PMID: 15657292).

Ustekinumab in Crohn's disease (2016): Feagan et al. demonstrated efficacy of combined IL-12/IL-23 (anti-p40) blockade in active Crohn's disease refractory to anti-TNF therapy, with STAT3 pathway marker correlations confirming mechanism (PMID: 27959607).

---

Current Research Frontiers

The IL-23/Microbiome Interface

Germ-free and gnotobiotic mouse studies have demonstrated that specific microbial taxa — particularly segmented filamentous bacteria (SFB) in mice and Prevotella copri in humans — drive DC IL-23 production and intestinal Th17 accumulation. The mechanistic link between microbial pattern recognition, DC IL-23 secretion, and downstream Th17 polarization is a major focus of mucosal immunology research.

Entheseal IL-23 Biology in Spondyloarthritis

The discovery that resident entheseal ILC3s and γδ T cells express IL-23R and respond locally — independent of systemic Th17 trafficking — has reframed how researchers model axSpA. Single-cell RNA sequencing of entheseal biopsy material has identified IL-23R+RORC+γδ T cells as the dominant local IL-23 responders, distinct from circulating Th17 populations.

TYK2 Pseudokinase Inhibition

Deucravacitinib's mechanism — allosteric inhibition of TYK2's regulatory pseudokinase domain rather than the active kinase domain — has generated interest in precision inhibition of IL-23 signaling without the selectivity liabilities of pan-JAK inhibitors. Research applications include dose-response comparisons with receptor-level blockade and combination studies with anti-p19 agents.

Single-Cell Resolution of IL-23 Circuits

Single-cell RNA sequencing datasets from psoriatic skin (revealing DC2-enriched IL-23A+ clusters), Crohn's disease biopsies (showing IL-23R+ ILC3/γδ T cell enrichment in inflamed mucosa), and synovial tissue have enabled cell-type-specific resolution of IL-23 source and responder populations, generating mechanistic hypotheses testable with RUO reagents.

IL-23 and Regulatory T Cell Reciprocity

Recent research has explored how IL-23 and TGF-β/IL-2-driven regulatory T cells (Tregs) reciprocally regulate each other — a balance critical for mucosal homeostasis. IL-23 suppresses Treg function and stability (by opposing TGF-β/STAT5 signaling), while Tregs limit DC IL-23 production through IL-10 and TGF-β feedback. Disruption of this balance is increasingly studied in IBD and cancer immunotherapy research contexts.

---

Summary

IL-23 is a pivotal immunomodulatory cytokine positioned at the convergence of innate microbial sensing and adaptive Th17 effector function. Its p19/p40 heterodimeric structure, the IL-23R/IL-12Rβ1 receptor complex, and the JAK2/TYK2-STAT3 signaling cascade define a therapeutic axis that has reshaped autoimmune disease research over the past two decades. The development of anti-p19 biologics — which selectively neutralize IL-23 without disrupting IL-12/IFN-γ-mediated protective immunity — represents a major translational validation of mechanistic cytokine research.

For laboratories investigating cytokine network biology, immune-mediated inflammatory diseases, tumor immunology, or the microbiome-host immune interface, IL-23 represents a research-critical molecular target with a mature ecosystem of recombinant proteins, blocking antibodies, reporter mice, and GWAS-validated genetic tools. Research use must adhere strictly to RUO standards — all IL-23 reagents and models described here are for laboratory research investigation only.

---

Content accurate as of 2026. All referenced biologics and cytokine reagents are for Research Use Only (RUO) — not for human or animal therapeutic application. Researchers should consult current PubMed literature for up-to-date primary data.